Encore Dermatology announced the launch of Impoyz Cream (clobetasol propionate) 0.025% for the treatment of moderate to severe plaque psoriasis in patients aged ≥18 years.
Impoyz Cream, a high-potency topical corticosteroid, was approved by the Food and Drug Administration (FDA) in December 2017. The FDA approval was supported by data from 2 double-blind, randomized, vehicle-controlled trials (N=532) in patients with moderate to severe plaque psoriasis (IGA 3 or 4 and BSA ≥3%). The most common adverse reaction associated with Impoyz Cream was application site discoloration.
Impoyz Cream can be used for up to 2 consecutive weeks; treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50g/week because of the potential for the drug to suppress the hypothalamic-pituitary axis. Treatment should be discontinued when psoriasis is controlled.
Impoyz Cream is available in 60g tubes.
For more information call (844) 848-6543 or visit EncoreDerm.com.
This article originally appeared on MPR